Mirum Pharmaceuticals (Nasdaq: MIRM) announced that its Phase 3 EXPAND study of maralixibat (Livmarli) met its primary endpoint in patients ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA

Baird on Mirum Pharmaceuticals (MIRM): 'we expect upside for the stock'October 12, 2026 9:34 AM